Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Ovarian Neoplasms 18 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Breast Neoplasms 6 Metastatic Castration-resistant Prostate Cancer 3 Fallopian Tube Neoplasms 3 Triple Negative Breast Neoplasms 2 Neoplasm Metastasis 2 Endometrial Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Carcinoma 2 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Hematologic Neoplasms 1 HER2-ve Metastatic Breast Cancer 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Olanzapine 4 Cyclophosphamide 4 Voriconazole 3 Tranexamic Acid 3 Standard of Care 3 nilotinib 2 letermovir 2 fludarabine phosphate 2 Zoledronic Acid 2 Whole-Body Irradiation 2 Practice Guidelines as Topic 2 Peripheral Blood Stem Cell Transplantation 2 Mycophenolic Acid 2 Methods 2 Imatinib Mesylate 2 Educational Status 2 Early Intervention, Educational 2 Doxorubicin 2 Cyclosporins 2 Cyclosporine 2 venetoclax 1 trihexyltetradecylphosphonium chloride 1 thymoglobulin 1 shengxuening 1 posaconazole 1 pembrolizumab 1 olaparib 1 maribavir 1 lenvatinib 1 ferrous succinate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Hematologic Neoplasms × olaparib × Clear all

NCT03486873 2026-05-26

MK-3475-587

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡